Arcellx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACLX research report →
Range $115 – $120
Price Chart
About the company
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial.
- CEO
- Rami Elghandour
- IPO
- 2022
- Employees
- 163
- HQ
- Redwood City, MD, US
Get TickerSpark's AI analysis on ACLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.73B
- P/E
- -28.27
- Fwd P/E
- 292.50
- PEG
- 0.44
- P/S
- 302.09
- P/B
- 16.10
- EV/EBITDA
- -34.09
- Div Yield
- 0.00%
- Gross Margin
- -64.81%
- Op Margin
- -1135.61%
- Net Margin
- -1027.25%
- ROE
- -55.42%
- ROIC
- -49.88%
Latest fiscal year · YoY change
- Revenue
- $22.29M-79.4%
- Gross Profit
- $15.61M-84.8%
- Op Income
- $-253,083,000
- Net Income
- $-228,934,000-113.3%
- EPS
- $-4.07-103.5%
- OCF Growth
- -151.9%
- FCF Growth
- -119.4%
- 52W High
- $115.13
- 52W Low
- $50.85
- 50D MA
- $112.62
- 200D MA
- $84.15
- Beta
- 0.25
- RSI (14)
- 80
- Avg Volume
- 1.45M
No earnings-call transcripts are available for ACLX yet.
- Free Float
- 73.4%
- Shares Outstanding
- 58.51M
- Float Shares
- 42.96M
of shares held by institutions
230 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.08M | ▲ 174.43K |
| Aju Ib Investment Co., Ltd. | 223.49K | 0 |
| Groupe La Francaise | 151.05K | ▲ 151.05K |
| Janus Henderson Group PLC | 90.28K | ▼ 829.30K |
| Cibra Capital Ltd | 88.62K | ▲ 88.62K |
| California State Teachers Retirement System | 34.89K | ▲ 7.77K |
| Bck Capital Management LP | 4.00K | ▲ 4.00K |
| Virginia Retirement Systems Et Al | 4.00K | ▲ 900 |
| Quest Partners LLC | 3.80K | ▲ 3.56K |
| Allostery Investments LP | 1.00K | ▼ 43.00K |
| Abich Financial Wealth Management LLC | 750 | ▲ 750 |
| Cwm, LLC | 77 | ▼ 124 |
Held by 19 ETFs
Biggest fund positions in ACLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Carroll Jill | other | 1,479,148 |
| Apr 28, 26 | Carroll Jill | sell | 11,459 |
| Apr 28, 26 | Carroll Jill | sell | 8,011 |
| Apr 28, 26 | Carroll Jill | sell | 9,174 |
| Apr 28, 26 | Behbahani Ali | other | 2,706 |
| Apr 28, 26 | Behbahani Ali | sell | 11,459 |
| Apr 28, 26 | Behbahani Ali | sell | 8,011 |
| Apr 28, 26 | Behbahani Ali | sell | 9,174 |
| Apr 28, 26 | Ware Olivia C | sell | 36,806 |
| Apr 28, 26 | Ware Olivia C | sell | 11,459 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACLX coverage
Recent articles, reports, and earnings notes.
Inside the Obsidian Therapeutics IPO: Reverse-Merger Setup, Risks, and Watchpoints
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.
Veraxa Biotech AG IPO: What Investors Need to Know
Veraxa Biotech AG Ordinary Shares (NASDAQ: VRXA) is expected to list on 2026-06-10, but the price range has not been disclosed. This is a SPAC business combination rather than a traditional IPO, with the story centered on a pre-commercial oncology pipeline. Bull case: a differentiated antibody-therapy platform; bear case: no product revenue yet and heavy financing needs.
Want a deeper read on ACLX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
businesswire.com · Apr 28
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
zacks.com · Apr 27
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts
defenseworld.net · Apr 24
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
businesswire.com · Apr 17
Banque Pictet & Cie SA Acquires Shares of 5,109 Arcellx, Inc. $ACLX
defenseworld.net · Apr 4
Gilead Extends Tender Offer to Acquire Arcellx
businesswire.com · Apr 1
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
prnewswire.com · Mar 19
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
globenewswire.com · Mar 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.